ClinicalTrials.gg
Enrolling by invitationNCT06332638Updated Mar 27, 2024

PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects

A Phase 1 interventional study of Tegoprazan 12.5mg and Tegoprazan 25mg in Healthy, sponsored by HK inno.N Corporation. Enrolling by invitation at 1 site in Korea, Republic of. Open to participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-27.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
All
01

Study summary

The primary objective of this study is to explore pharmacokinetics, pharmacodynamics, and safety of tegoprazan 12.5 mg in healthy subjects when orally administered as a single dose or as multiple doses twice daily.

Read the detailed description

The secondary objectives of this study are

  • To compare pharmacokinetics and pharmacodynamics of tegoprazan 12.5 mg in healthy subjects between oral multiple-dose administration twice daily for 1 day and oral single-dose administration.
  • To evaluate pharmacokinetics and pharmacodynamics of tegoprazan 12.5 mg administered orally twice daily for 14 days in healthy subjects in comparison with tegoprazan 25 mg administered orally once daily for 14 days in healthy subjects.
  • To evaluate pharmacodynamics of tegoprazan 12.5 mg administered orally twice daily for 14 days or tegoprazan 25 mg administered orally once daily for 14 days in healthy subjects in comparison with famotidine 20 mg administered orally twice daily for 14 days in healthy subjects.
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adults aged ≥ 19 years to ≤ 45 years at the time of screening testing
  2. (BMI) ≥ 18.5 kg/m2 to ≤ 28.0 kg/m2 (BMI = weight (kg) / height (m)2)
  3. Those who have been fully informed of study purpose and procedures, properties of the products(IPs), etc. and have voluntarily decide to participate in this study and signed an form (ICF), prior to participation in the study

Exclusion criteria

Exclusion Criteria:

  1. Medical history

    1. Previous history or presence of hepatic, renal, gastrointestinal, respiratory, musculoskeletal, endocrine, neuropsychiatric, hemato-oncologic, urinary and cardiovascular (including cardiac arrhythmia) disorders in the judgment of the investigator
    2. Previous history of gastrointestinal diseases (e.g., gastritis, gastrospasm, gastroesophageal reflux disease (GERD), Crohn's disease, ulcers, etc.) or abdominal surgery (excluding simple appendectomy or hernia surgery) which may affect drug absorption in the judgment of the investigator
    3. Presence of anatomical disorders that make it difficult to insert and maintain a catheter for intragastric pH measurement, or expected intolerance to catheterization for intragastric pH measurement
    4. Hereditary problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  2. Clinical laboratory tests and (ECG)

    1. or ALT value ≥ 1.5 x (ULN) as a result of clinical laboratory testing at screening
    2. Total value ≥ 2.0 x upper limit of normal (ULN) as a result of clinical laboratory testing at screening
    3. value calculated using the CKD-EPI formula \< 80 mL/min as a result of clinical laboratory testing at screening
    4. Any clinically significant abnormality as a result of ECG at screening
    5. Positive test result for H. pylori at screening
  3. Allergies and drug abuse

    1. History of to the IPs, components of the IPs, and other drugs (benzimidazoles, H2 receptor antagonists, aspirin, antibiotics, etc.)
    2. Previous history of drug abuse or positive drug screening test result
  4. Prohibited concomitant medications/diets

    1. Consumption of medicines (including herbal medicines) or abnormal diets (e.g., at least 1L/day of grapefruit juice, much garlic, broccoli, kale, etc.) which may affect the absorption, distribution, metabolism, and excretion of the IP within 28 days before the screening visit
    2. Administration of the drugs affecting gastric pH within 14 days before the screening visit (including potassium-competitive acid blockers, proton pump inhibitors, H2-receptor antagonists, and antacids) or administration of ethical-the-counter (ETC) drugs, any over-the-counter (OTC) drugs, vitamins, etc. within 10 days before the screening visit
    3. Administration of another IP by participating in another clinical trial within 6 months prior to the screening visit (but those who are not administered the IP can participate in this study)
  5. Blood donation and transfusion

    1. Whole blood donation within 60 days before the screening visit
    2. Blood component donation or transfusion within 30 days before the screening visit
  6. Pregnancy, breastfeeding, and non-use of

    1. Pregnant women, women who tested positive for pregnancy, or breastfeeding women
    2. Failure to use medically recognized and proper double contraceptive methods or medically acceptable contraceptive methods (intrauterine device showing a demonstrated pregnancy failure rate, combined use of physical barrier method and spermicide, vasectomy, salpingectomy/tubal ligation, hysterectomy, etc.) in the subject or his/her spouse or partner from the date of screening visit until 30 days after the last dose of the IP
  7. Others

    1. Mean alcohol intake exceeding 30 g/day per week for recent 4 weeks before the screening visit or positive alcohol breath test result
    2. Mean number of smoked cigarettes exceeding 10 cigarettes/day per week for recent 4 weeks before the screening visit
    3. Mean caffeine intake exceeding 400 mg/day per week for recent 4 weeks before the screening visit
    4. Presence of clinically significant findings that make the subject ineligible for this study in the judgment of the investigator
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Group A

    Tegoprazan 12.5mg

    Drug: Tegoprazan 12.5mg

  • Active comparator
    Group B

    Tegoprazan 25mg

    Drug: Tegoprazan 25mg

  • Active comparator
    Group C

    Famotidine 20mg

    Drug: Famotidine 20mg

Interventions

  • Oral administration of one tablet of Tegoprazan 12.5mg twice daily for 14 days.

    Also known as: Tegoprazan Tab. 12.5mg

  • Oral administration of one tablet of Tegoprazan 25mg once daily for 14 days.

    Also known as: K-CAB Tab. 25mg

  • Oral administration of one tablet of Famotidine 20mg twice daily for 14 days.

    Also known as: Gaster Tab. 20 mg Dong-A

06

What researchers measure

Primary outcomes

  1. Cmax of tegoprazan and tegoprazan's metabolite M1

    Pharmacokinetic evaluation (Day 1)

    Time frame: Pre-dose(0 hour) up to 24 hours on Day 1

  2. AUC0-t of tegoprazan and tegoprazan's metabolite M1

    Pharmacokinetic evaluation (Day 1)

    Time frame: Pre-dose(0 hour) up to 24 hours on Day 1

  3. AUC0-∞ of tegoprazan and tegoprazan's metabolite M1

    Pharmacokinetic evaluation (Day 1)

    Time frame: Pre-dose(0 hour) up to 24 hours on Day 1

  4. Tmax of tegoprazan and tegoprazan's metabolite M1

    Pharmacokinetic evaluation (Day 1)

    Time frame: Pre-dose(0 hour) up to 24 hours on Day 1

  5. t1/2β of tegoprazan and tegoprazan's metabolite M1

    Pharmacokinetic evaluation (Day 1)

    Time frame: Pre-dose(0 hour) up to 24 hours on Day 1

  6. CL/F of tegoprazan

    Pharmacokinetic evaluation (Day 1)

    Time frame: Pre-dose(0 hour) up to 24 hours on Day 1

  7. Vd/F of tegoprazan

    Pharmacokinetic evaluation (Day 1)

    Time frame: Pre-dose(0 hour) up to 24 hours on Day 1

  8. Css,max of tegoprazan and tegoprazan's metabolite M1

    Pharmacokinetic evaluation (Day 14)

    Time frame: Pre-dose(morning) (-12, 0 hour) up to 24 hours on Day 14

  9. Css,min of tegoprazan and tegoprazan's metabolite M1

    Pharmacokinetic evaluation (Day 14)

    Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14

  10. Css,avg of tegoprazan and tegoprazan's metabolite M1

    Pharmacokinetic evaluation (Day 14)

    Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14

  11. AUCtau,ss of tegoprazan and tegoprazan's metabolite M1

    Pharmacokinetic evaluation (Day 14)

    Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14

  12. Tmax,ss of tegoprazan and tegoprazan's metabolite M1

    Pharmacokinetic evaluation (Day 14)

    Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14

  13. t1/2β,ss of tegoprazan and tegoprazan's metabolite M1

    Pharmacokinetic evaluation (Day 14)

    Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14

  14. CLss/F of tegoprazan

    Pharmacokinetic evaluation (Day 14)

    Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14

  15. Vdss/F of tegoprazan

    Pharmacokinetic evaluation (Day 14)

    Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14

  16. Accumulation index of tegoprazan

    Pharmacokinetic evaluation (Day 14)

    Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14

  17. Fluctuation of tegoprazan

    Pharmacokinetic evaluation (Day 14)

    Time frame: Pre-dose(morning)(-12, 0 hour) up to 24 hours on Day 14

Secondary outcomes

  1. 24-hour, daytime and nighttime mean pH

    Pharmacodynamic evaluation

    Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14

  2. 24-hour, daytime and nighttime median pH

    Pharmacodynamic evaluation

    Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14

  3. 24-hour, daytime and nighttime TpH>3(%)

    Pharmacodynamic evaluation

    Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14

  4. 24-hour, daytime and nighttime TpH>4(%)

    Pharmacodynamic evaluation

    Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14

  5. 24-hour, daytime and nighttime Δ TpH>3(%)

    Pharmacodynamic evaluation

    Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14

  6. 24-hour, daytime and nighttime Δ TpH>4(%)

    Pharmacodynamic evaluation

    Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14

  7. 24-hour, daytime and nighttime Δ mean pH

    Pharmacodynamic evaluation

    Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14

  8. 24-hour, daytime and nighttime Δ median pH

    Pharmacodynamic evaluation

    Time frame: 24 hours on Day -1, Day 1, Day 7, and Day 14

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Jul 2024, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Mar 27, 2024
StartActual
Mar 19, 2024
Primary completionEst.
Jul 31, 2024
CompletionEst.
Jul 31, 2024
Last update
Mar 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06332638
Responsible party
Sponsor
First posted
Mar 27, 2024
Start date
Mar 19, 2024
Primary completion
Jul 31, 2024 (estimated)
Completion
Jul 31, 2024 (estimated)
Last update
Mar 27, 2024

Study contacts

Jong Lyul Ghim, MD, PhD
principal investigator · Department of Clinical Pharmacology, Inje University Busan Paik Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion